The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Assessing the dynamics of CD8-expressing cells in patients with R/R LBCL treated with glofitamab
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the structure and aims of an imaging study (NCT03533283) assessing the distribution and dynamics of CD8-expressing T-cells in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) before and after treatment with glofitamab. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Genmab: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; AbbVie: Consultancy; Incyte: Research Funding; Janssen: Consultancy, Research Funding; AbbVie, Celgene, Genmab, Janssen, Roche, Takeda: Membership on an entity’s Board of Directors or advisory committees; Genentech: Research Funding; Novartis: Research Funding; Celgene, Genentech, Genmab, Incyte, Janssen, Novartis, Roche, Takeda: Research Funding; Roche: Consultancy, Research Funding; Takeda: Consultancy, Research Funding.
